Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 FDG-PET imaging in the diagnosis of HIV-associated multicentric Castleman disease: something is still missing.

Literature DB >> 22954613

FDG-PET imaging in the diagnosis of HIV-associated multicentric Castleman disease: something is still missing.

Roberto Rossotti¹, Christina Moioli, Clara Schiantarelli, Carloandrea Orcese, Massimo Puoti.

Abstract

Now that [18F] fluorodeoxyglucose positron emission tomography (FDG-PET) has become an established imaging tool in oncology, it is attracting interest in the field of infectious diseases. Several studies have used FDG-PET to examine the pathophysiology of HIV infection as well as other conditions such as lipodystrophic syndrome and HIV-related neurocognitive disorders. In clinical practice, FDG-PET has been proposed to assess fever of unknown origin or with lymphoproliferative disorders such as Castleman disease in individuals with HIV infection.

Entities: Chemical Disease

Mesh：

Substances：
Fluorodeoxyglucose F18

Year: 2012 PMID： 22954613 PMCID： PMC6148946

Source DB: PubMed Journal: Top Antivir Med ISSN： 2161-5853

19 in total

1. FDG positron emission tomographic scintigraphy can reveal Castleman's disease as a cause of inflammation.

Authors: D Blockmans; A Maes; S Stroobants; H Bobbaers; L Mortelmans
Journal: Clin Nucl Med Date: 2001-11 Impact factor: 7.794

2. Unicentric and multicentric Castleman's disease.

Authors: K Enomoto; I Nakamichi; K Hamada; A Inoue; I Higuchi; M Sekimoto; M Mizuki; Y Hoshida; T Kubo; K Aozasa; J Hatazawa
Journal: Br J Radiol Date: 2007-01 Impact factor: 3.039

3. 18F-FDG PET and PET/CT in fever of unknown origin.

Authors: Johannes Meller; Carsten-Oliver Sahlmann; Alexander Konrad Scheel
Journal: J Nucl Med Date: 2007-01 Impact factor: 10.057

4. FDG-PET/CT imaging in the management of HIV-associated multicentric Castleman's disease.

Authors: Rob Barker; Fahrad Kazmi; Justin Stebbing; Sarah Ngan; Roger Chinn; Mark Nelson; Michael O'Doherty; Mark Bower
Journal: Eur J Nucl Med Mol Imaging Date: 2008-12-03 Impact factor: 9.236

5. HHV-8 is not associated with follicular dendritic cell tumours.

Authors: S J Nayler; L Taylor; K Cooper
Journal: Mol Pathol Date: 1998-06

6. How I treat HIV-associated multicentric Castleman disease.

Authors: Mark Bower
Journal: Blood Date: 2010-08-05 Impact factor: 22.113

Review 7. HIV-associated multicentric Castleman disease.

Authors: Deepa Reddy; Ronald Mitsuyasu
Journal: Curr Opin Oncol Date: 2011-09 Impact factor: 3.645

8. Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy.

Authors: Frits van Rhee; Katie Stone; Susann Szmania; Bart Barlogie; Zeba Singh
Journal: Clin Adv Hematol Oncol Date: 2010-07

Review 9. Castleman disease: an update on classification and the spectrum of associated lesions.

Authors: Danielle M P Cronin; Roger A Warnke
Journal: Adv Anat Pathol Date: 2009-07 Impact factor: 3.875

10. Clinical Manifestations of Kaposi Sarcoma Herpesvirus Lytic Activation: Multicentric Castleman Disease (KSHV-MCD) and the KSHV Inflammatory Cytokine Syndrome.

Authors: Mark N Polizzotto; Thomas S Uldrick; Duosha Hu; Robert Yarchoan
Journal: Front Microbiol Date: 2012-03-02 Impact factor: 5.640

4 in total

1. Laparoscopic treatment for retroperitoneal hyaline-vascular type localized Castleman's disease (LCD) in the iliac vessel region.

Authors: Aiwen Le; Lili Shan; Zhonghai Wang; Xiaoyun Dai; Tianhui Xiao; Rong Zhuo; Rui Yuan
Journal: Int J Clin Exp Med Date: 2015-11-15